A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Conditions
Chronic Myelomonocytic Leukemia · Chronic Myelomonocytic Leukemia (CMML) · Chronic Myelomonocytic Leukemia-1 · Chronic Myelomonocytic Leukemia-2 · Refractory Chronic Myelomonocytic Leukemia · CMML · Acute Myeloid Leukemia · Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia Post Cytotoxic Therapy · Acute Myeloid Leukemias · Refractory Acute Myeloid Leukemia (AML) · Acute Monocytic Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Stanford University, Stanford, California, United States
Contact: Principal Investigator (Principal Investigator, MD)Moffitt, Tampa, Florida, United States
Contact: Principal Investigator (Principal Investigator, MD)DFCI, Boston, Massachusetts, United States
Contact: Principal Investigator (Principal Investigator, MD)Mayo Clinic, Rochester, Minnesota, United States
Contact: Principal Investigator (Principal Investigator, MBBS)OHSU, Portland, Oregon, United States
Contact: Principal Investigator (Principal Investigator, MD)Vanderbilt University, Nashville, Tennessee, United States
Contact: Principal Investigator (Principal Investigator, MBBS)MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Principal Investigator, MD)
Study leads
Chief Medical Officer, MD, MSc, MBA
Study Director
Solu Therapeutics